Sionna Therapeutics (NASDAQ:SION) Raised to “Strong-Buy” at Wedbush

Sionna Therapeutics (NASDAQ:SION) was upgraded by equities researchers at Wedbush to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

A number of other analysts have also issued reports on SION. Raymond James Financial restated a “strong-buy” rating and issued a $53.00 price target on shares of Sionna Therapeutics in a research note on Monday, January 5th. UBS Group reissued a “buy” rating on shares of Sionna Therapeutics in a report on Monday, March 2nd. Citizens Jmp started coverage on shares of Sionna Therapeutics in a research report on Tuesday, February 24th. They issued a “market outperform” rating and a $63.00 target price for the company. JonesTrading upped their target price on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Finally, BTIG Research reaffirmed a “buy” rating and set a $58.00 price target on shares of Sionna Therapeutics in a research report on Monday, April 27th. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $53.00.

Sionna Therapeutics Stock Up 1.3%

Shares of NASDAQ SION opened at $40.97 on Monday. Sionna Therapeutics has a fifty-two week low of $11.77 and a fifty-two week high of $46.46. The business has a 50 day moving average price of $38.29 and a two-hundred day moving average price of $39.20. The firm has a market cap of $1.85 billion, a PE ratio of -21.01 and a beta of 1.35.

Sionna Therapeutics (NASDAQ:SION) last announced its earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.15. On average, analysts anticipate that Sionna Therapeutics will post -2.44 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Orbimed Advisors Llc sold 2,948 shares of the firm’s stock in a transaction dated Saturday, April 18th. The shares were sold at an average price of $44.52, for a total value of $131,244.96. Following the transaction, the director directly owned 2,964,774 shares in the company, valued at approximately $131,991,738.48. This trade represents a 0.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 2,948 shares of Sionna Therapeutics stock in a transaction dated Saturday, April 18th. The shares were sold at an average price of $44.52, for a total transaction of $131,244.96. Following the completion of the transaction, the director directly owned 2,964,774 shares of the company’s stock, valued at $131,991,738.48. This trade represents a 0.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,131,856 shares of company stock worth $50,834,773 over the last three months. 3.90% of the stock is owned by corporate insiders.

Institutional Trading of Sionna Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in SION. Eventide Asset Management LLC bought a new position in Sionna Therapeutics during the fourth quarter valued at about $26,290,000. Vanguard Group Inc. lifted its holdings in Sionna Therapeutics by 81.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock valued at $33,620,000 after acquiring an additional 512,803 shares during the last quarter. State Street Corp boosted its position in shares of Sionna Therapeutics by 188.7% during the 4th quarter. State Street Corp now owns 693,395 shares of the company’s stock valued at $28,526,000 after purchasing an additional 453,196 shares in the last quarter. Viking Global Investors LP grew its stake in shares of Sionna Therapeutics by 8.2% in the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after purchasing an additional 242,427 shares during the last quarter. Finally, Candriam S.C.A. acquired a new position in shares of Sionna Therapeutics in the 1st quarter worth approximately $9,494,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.